Legal entity
Negative sentiment reaches 67% here, compared with 38% across the 1552-story beat baseline for the same window. regulation accounts for 4 of the 6 tracked stories, while 1 other category carries the remainder. mifepristone is most often covered alongside FDA, which appears in 2 of these 6 stories.
Last mentioned: Sep 10, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Negative sentiment reaches 67% here, compared with 38% across the 1552-story beat baseline for the same window. regulation accounts for 4 of the 6 tracked stories, while 1 other category carries the remainder. mifepristone is most often covered alongside FDA, which appears in 2 of these 6 stories. Source depth averages 2.3 original sources per story, versus 3.3 across the same-window beat baseline. The 182-day window averages about 0.2 stories each week. The busiest single day carried 2. At 7, the average consequence score sits above the same-window beat average of 6.2. We currently track 6 Legal stories that mention mifepristone, published between March 13, 2026 and September 10, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 1552 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mifepristone. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Fifth Circuit hears Louisiana v. FDA
The U.S. Court of Appeals for the Fifth Circuit in New Orleans holds oral arguments in a case that could end telehealth mifepristone access nationwide.
Choices Women's Center launches telehealth
Dr. Richardson begins offering telehealth abortion services at his Tucson clinic, and adoption takes off with 95% of patients choosing telemedicine.
Murder Charge Filed
A woman is arrested and charged with murder for self-inducing an abortion with medication.
Missouri Stay Request
DOJ files request in Missouri court to pause litigation pending FDA review.
Legislative Action
Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Arizona court clears telehealth abortion
A judge rules in favor of Dr. William Richardson in a lawsuit filed by the Center for Reproductive Rights, removing state restrictions on telehealth mifepristone in Arizona.
Louisiana Request
DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.
Amended Complaint
AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
SCOTUS Ruling
Supreme Court dismisses challenge to mifepristone access on standing grounds, preserving status quo.
Retail Pharmacy Entry
Major chains CVS and Walgreens receive certification to dispense abortion pills.
FDA makes telehealth mifepristone rule official
The FDA formally codifies the policy allowing mifepristone to be prescribed via telehealth and dispensed by mail.
LIFE Act Implementation
The 11th Circuit Court of Appeals allows Georgia's 6-week ban and personhood provisions to take effect.
Dobbs Decision
The U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans to take effect.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
Telehealth Expansion
FDA permanently removes in-person dispensing requirements, allowing mail-order access.
FDA begins allowing telehealth mifepristone
During the COVID-19 pandemic, the FDA begins allowing the abortion pill mifepristone to be prescribed through telehealth and sent to patients in the mail.
LIFE Act Signed
Georgia Governor Brian Kemp signs the Living Infants Fairness and Equality (LIFE) Act.
The Fifth Circuit is hearing Louisiana v. FDA, a case that could invalidate the FDA's 2023 telehealth mifepristone rule nationwide. For legal and regulatory professionals, it tests federal agency authority, state standing, and the durability of telehealth abortion access.
A Fifth Circuit panel is weighing whether federal courts or the FDA should govern mifepristone prescribing, with state shield laws and cross-border pill access at issue. The case is one of three appeals seeking to restrict medication abortion.
Medication abortion now accounts for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and state shield laws. This shift has triggered a wave of regulatory counter-measures from opponents, focusing on the Comstock Act and FDA approval processes.
Source: yahoo.com · mykxlg.com
A Georgia woman faces malice murder charges after allegedly using medication to induce an abortion, marking a significant escalation in the criminalization of reproductive care. This case tests the boundaries of state 'fetal personhood' laws and creates a high-stakes precedent for the intersection of digital privacy and law enforcement.
Source: news4jax.com · mdjonline.com
House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services.
Source: Alanna Vagianos (ca) · Alanna Vagianos (ca)
The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
Source: Danielle Han (us) · yahoo.com
mifepristone is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
